Consolidated Balance Sheets - USD ($)		Dec. 31, 2025	Dec. 31, 2024
Current Assets
Cash		$ 5,334,322	$ 3,325,131
Advances on research and development contract services		208,972	258,059
Prepaid insurance		232,946	268,179
Interest Receivable		9,895
Prepaid expenses		10,000	10,000
Total current assets		5,796,135	3,861,369
Total assets		5,796,135	3,861,369
Current Liabilities
Accounts payable and accrued expenses		417,884	373,042
Warrant liability		703	4,670
Total current liabilities		418,587	377,712
Total liabilities		418,587	377,712
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2025 and 2024
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at December 31, 2025 and 2024, respectively	[1]	1,795	492
Additional paid-in capital	[1]	93,506,122	88,504,543
Accumulated deficit		(88,130,369)	(85,021,378)
Total stockholders’ equity		5,377,548	3,483,657
Total liabilities and stockholders’ equity		$ 5,796,135	$ 3,861,369

[1] Adjusted to reflect the reverse stock split as described in Note 1.